In Reply to Rans et  al

We appreciate the comments made by Rans et  al1 and concur that the difference in cumulative incidence of local relapse in our phase 3 randomized study2 reflects the increased biologically effective dose (BED) of 24 Gy single-dose radiation therapy (SDRT) compared with 3 × 9 Gy stereotactic body radiation therapy. When this protocol was de signed, there was already evidence from our early phase 1-2 SDRT studies3,4 that 24 Gy SDRT achieved high rates of prolonged local relapse-free survival, apparently superior to lower BED SDRT or low- to intermediate-BED multifraction stereotactic body radiation therapy regimens.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comments Source Type: research